Fort Sheridan Advisors’s Sangamo Therapeutics SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.89K | Sell |
12,723
-2,418
| -16% | -$1.31K | ﹤0.01% | 253 |
|
|
2025
Q1 | $9.93K | Sell |
15,141
-7,880
| -34% | -$5.17K | ﹤0.01% | 248 |
|
|
2024
Q4 | $23.5K | Sell |
23,021
-110
| -0.5% | -$112 | ﹤0.01% | 245 |
|
|
2024
Q3 | $20K | Buy |
23,131
+1,310
| +6% | +$1.14K | ﹤0.01% | 248 |
|
|
2024
Q2 | $7.82K | Sell |
21,821
-200
| -0.9% | -$72 | ﹤0.01% | 235 |
|
|
2024
Q1 | $14.8K | Sell |
22,021
-4,357
| -17% | -$2.92K | ﹤0.01% | 206 |
|
|
2023
Q4 | $14.3K | Sell |
26,378
-27,453
| -51% | -$14.9K | ﹤0.01% | 200 |
|
|
2023
Q3 | $32.3K | Sell |
53,831
-12,655
| -19% | -$7.59K | 0.01% | 194 |
|
|
2023
Q2 | $86.4K | Buy |
66,486
+8,688
| +15% | +$11.3K | 0.02% | 202 |
|
|
2023
Q1 | $102K | Sell |
57,798
-1,205
| -2% | -$2.12K | 0.03% | 192 |
|
|
2022
Q4 | $185K | Sell |
59,003
-15,048
| -20% | -$47.3K | 0.06% | 175 |
|
|
2022
Q3 | $363K | Sell |
74,051
-327
| -0.4% | -$1.6K | 0.12% | 120 |
|
|
2022
Q2 | $308K | Buy |
74,378
+400
| +0.5% | +$1.66K | 0.1% | 132 |
|
|
2022
Q1 | $430K | Sell |
73,978
-920
| -1% | -$5.35K | 0.13% | 111 |
|
|
2021
Q4 | $562K | Sell |
74,898
-1,939
| -3% | -$14.5K | 0.16% | 101 |
|
|
2021
Q3 | $692K | Sell |
76,837
-843
| -1% | -$7.59K | 0.23% | 78 |
|
|
2021
Q2 | $930K | Buy |
77,680
+1,735
| +2% | +$20.8K | 0.31% | 54 |
|
|
2021
Q1 | $952K | Buy |
75,945
+4,772
| +7% | +$59.8K | 0.38% | 51 |
|
|
2020
Q4 | $1.11M | Buy |
71,173
+9,540
| +15% | +$149K | 0.54% | 31 |
|
|
2020
Q3 | $582K | Buy |
61,633
+17,478
| +40% | +$165K | 0.34% | 47 |
|
|
2020
Q2 | $396K | Buy |
44,155
+1,880
| +4% | +$16.9K | 0.24% | 59 |
|
|
2020
Q1 | $269K | Buy |
42,275
+14,578
| +53% | +$92.8K | 0.2% | 62 |
|
|
2019
Q4 | $232K | Buy |
27,697
+4,370
| +19% | +$36.6K | 0.12% | 95 |
|
|
2019
Q3 | $211K | Buy |
+23,327
| New | +$211K | 0.12% | 89 |
|